File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1093/annonc/mdu174
- Scopus: eid_2-s2.0-84905162106
- PMID: 24827127
- WOS: WOS:000340101600020
Supplementary
- Citations:
- Appears in Collections:
Article: Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer
Title | Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer |
---|---|
Authors | |
Keywords | Biomarker Eribulin Erlotinib Non-small-cell lung cancer Platinum-based doublet chemotherapy |
Issue Date | 2014 |
Citation | Annals of Oncology, 2014, v. 25, p. 1578-1584 How to Cite? |
Persistent Identifier | http://hdl.handle.net/10722/202738 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Mok, TS | en_US |
dc.contributor.author | Geater, SL | en_US |
dc.contributor.author | Iannotti, N | en_US |
dc.contributor.author | Thongprasert, S | en_US |
dc.contributor.author | Spira, A | en_US |
dc.contributor.author | Smith, D | en_US |
dc.contributor.author | Lee, VHF | en_US |
dc.contributor.author | Lim, WT | en_US |
dc.contributor.author | Reyderman, L | en_US |
dc.contributor.author | Wang, B | en_US |
dc.date.accessioned | 2014-09-19T09:33:32Z | - |
dc.date.available | 2014-09-19T09:33:32Z | - |
dc.date.issued | 2014 | en_US |
dc.identifier.citation | Annals of Oncology, 2014, v. 25, p. 1578-1584 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/202738 | - |
dc.language | eng | en_US |
dc.relation.ispartof | Annals of Oncology | en_US |
dc.subject | Biomarker | - |
dc.subject | Eribulin | - |
dc.subject | Erlotinib | - |
dc.subject | Non-small-cell lung cancer | - |
dc.subject | Platinum-based doublet chemotherapy | - |
dc.title | Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer | en_US |
dc.type | Article | en_US |
dc.identifier.email | Lee, VHF: vhflee@hku.hk | en_US |
dc.identifier.authority | Lee, VHF=rp00264 | en_US |
dc.identifier.doi | 10.1093/annonc/mdu174 | en_US |
dc.identifier.pmid | 24827127 | - |
dc.identifier.scopus | eid_2-s2.0-84905162106 | - |
dc.identifier.hkuros | 237796 | en_US |
dc.identifier.volume | 25 | en_US |
dc.identifier.spage | 1578 | en_US |
dc.identifier.epage | 1584 | en_US |
dc.identifier.isi | WOS:000340101600020 | - |